Evidence map›Paper›PMID 42031711›Full record

ArticleCell death discovery2026

AURKA/PHB2 signaling drives acquired resistance to KRAS

Jinrong Liao, Xin Lan, Zeng Chen, Dan Hu, Doudou Luo, Huocong He, Zhiyi Huang, Hongyu Yu, Yunpeng Bai, Xingguang Luo and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell death discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jinrong Liao *Laboratory of Radiation Oncology and Radiobiology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
Xin Lan *College of Chemistry, Fuzhou University, Fuzhou, China.ORCID http://orcid.org/0009-0006-8604-5796
Zeng Chen *Laboratory of Radiation Oncology and Radiobiology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
Dan HuDepartment of Pathology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
Doudou LuoKey Laboratory of Microbial Pathogenesis and Interventions of Fujian Province University, the Key Laboratory of Innate Immune Biology of Fujian Province, Biomedical Research Center of South China, College of Life Sciences, Fujian Normal University, Fuzhou, China.
Huocong HeLaboratory of Radiation Oncology and Radiobiology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
Zhiyi HuangCollege of Chemistry, Fuzhou University, Fuzhou, China.
Hongyu YuFujian Medical University, Fuzhou, China.
Yunpeng BaiLaboratory Animal Center. Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
Xingguang LuoBeijing Huilongguan Hospital, Beijing University Huilongguan School of Clinical Medicine, Beijing, China.ORCID http://orcid.org/0000-0003-3585-042X
Xiandong LinLaboratory of Radiation Oncology and Radiobiology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China. linxdong1970@fjzlhospital.com.ORCID http://orcid.org/0000-0002-3250-4014

Funding

Natural Science Foundation of Fujian Province (Fujian Provincial Natural Science Foundation) 2019J01196, 2020J011109, 2024J011063
6 · The paper itself

Abstract

Patients with non-small cell lung cancer (NSCLC) who initially respond to Sotorasib, a drug targeting the KRAS

Identifiers

PMID42031711
PMCPMC13247048

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.